C4 Therapeutics,

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA. The listed name for CCCC is C4 Therapeutics, Inc. Common Stock.

 

To recover

 

ZOM as of 17 November 2023 NL 423.42

• 

ZOM	718.2 $
798 sh	totalstock
$0.37	market
$0.90	avg
$423.42	netloss
$294.86	equity

The company also converted the preferred shares to common shares ending the overhang from the instruments, which were entitled to 9 percent royalty of the sales. 

ZOM stock’s forecast looks positive if we stretch it to 2025.

 In the past, I said that ZOM stock looks like a good long-term investment.

 My only concern was with the price.

Daily  trade volume 3.67 M

average volume 5.65 

as of 03/20/2024

• Open	0.1295
  High	0.1350
  Low	0.1295

• Mkt Cap	130.14M
  P/E (TTM)	N/A
  Div & Yield	N/A & N/A

• Prev. Close	0.1280
  52 Wk. Low	0.1200
  52 Wk. High	0.2450

  
  
• 
  

 

 

ZOM	718.2 $
798 sh	totalstock
$0.37	market
$0.90	avg
$423.42	netloss
$294.86	equity

  

STOCK -FILL THE SHORT TABLE

ID	STOCK	REMARK PRICE	Field3	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
238	zom		RH	$0.18	1200	$221.28	1000	$0.15	$151.70	$372.98	2200	$0.17	0

STOCK -FILL THE SHORT TABLE

ID	STOCK	REMARK PRICE	Field3	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
281	ZOM		RH	$0.90	798	$718.20	10000	$0.32	$3,183.00	$3,901.20	10798	$0.36	0

STOCK -FILL THE SHORT TABLE

ID	STOCK	REMARK PRICE	Field3	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
174	ZOM	DOWN LOWEST AT 0.1722 (12/02/2020)	RH	$0.19	1000	$189.00	1000	$0.13	$130.00	$319.00	2000	$0.16	0	GAP 0.3
238	ZOM		RH	$0.18	1200	$221.28	1000	$0.15	$151.70	$372.98	2200	$0.17	0
281	ZOM		RH	$0.90	798	$718.20	5000	$0.32	$1,591.50	$2,309.70	5798	$0.40	0

SHOT-Safety Shot as of November 09 2023

 

 

PLUG 52 week low

 

TCRT as of November11/06/2023 net loss 39$

 

FcEL as of Nov 6 2023

Current Price: $1.06 per share1.

Previous Close: $1.07 per share.

Day’s Range: $1.03 - $1.09.

52-Week Range: $0.98 - $3.03.

Market Cap: Approximately $478.97 million.

Earnings Date: Expected between June 6, 2024, and June 10, 2024.

EPS (TTM): Reported as -$0.26 in the most recent earnings call1.

Performance Outlook:

Short Term (2 weeks to 6 weeks): Neutral.

Mid Term (6 weeks to 9 months): Negative.

Long Term (9 months and beyond): Negative.

Fair Value Estimate: Not available.

Beta (5Y Monthly): 3.74.

   

SPRO To get in again

to get in again

 

weekly study

 

PLUG as of 02 Nov 2023